Endogenex key facts
as of Oct 2026- Developer of a medical device system designed to improve metabolic function in individuals with diabetes by resetting metabolic signalling in the small intestine.
- Endogenex is valued at approximately $218.0M as of Oct 2026, set at its later-stage round, Mar 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $190.4M across 3 recorded rounds; the latest was Later Stage VC ($69.6M) in Jun 2024.
- Notable investors include Hatteras Venture Partners, Mayo Clinic Ventures, Arboretum Ventures, Longitude Capital, Fourth Element Capital — 11 tracked in total.
- Endogenex has filed 3 Form Ds with the SEC since 2023, most recently Jun 2024 ($69.6M sold to 11 investors).
- Status: Privately Held (backing).
Valued at $218.0M at its later-stage round, Mar 2026. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch Endogenex: the Monday email on marks, rounds and moves
Endogenex funding rounds
3 roundsWho backs Endogenex
11+Endogenex valuation
Endogenex was valued at $218 million at its later-stage round in Mar 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Endogenex raised?
Endogenex has raised $190 million across 3 recorded rounds since 2023. The largest was a $9.2 million early-stage round in Feb 2023; the most recent was a $69.6 million later-stage round in Jun 2024.
Endogenex has filed 3 Form Ds with the SEC since 2023, most recently in Jun 2024 ($69.6 million sold to 11 investors).
Endogenex investors
11 investors are on record for Endogenex, including Hatteras Venture Partners, Mayo Clinic Ventures, Arboretum Ventures and Longitude Capital. The later-stage round in Jun 2024 drew 11 investors.
About Endogenex
Developer of a medical device system designed to improve metabolic function in individuals with diabetes by resetting metabolic signalling in the small intestine. The company's device delivers controlled, non-thermal pulsed electric fields through an endoscopic procedure to promote duodenal tissue regeneration, enabling patients with type 2 diabetes to better manage blood glucose and support metabolic health.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2017
- Employees
- 28
- Website
- endogenex.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.